William Blair Brokers Lower Earnings Estimates for TARS

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Stock analysts at William Blair dropped their Q2 2025 EPS estimates for Tarsus Pharmaceuticals in a research report issued on Monday, July 14th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings per share of ($0.48) for the quarter, down from their previous estimate of ($0.43). The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ FY2025 earnings at ($1.43) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 39.72% and a negative net margin of 44.91%. The company had revenue of $78.34 million during the quarter, compared to analysts’ expectations of $72.50 million.

Other equities analysts have also recently issued research reports about the company. Guggenheim boosted their price target on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. The Goldman Sachs Group increased their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a “neutral” rating in a research report on Monday, May 5th. HC Wainwright upgraded Tarsus Pharmaceuticals to a “buy” rating and set a $72.00 price target for the company in a report on Tuesday, May 27th. Finally, Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a research note on Monday, June 2nd. They issued an “outperform” rating and a $75.00 price objective for the company. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $66.67.

Tarsus Pharmaceuticals Stock Up 2.4%

Shares of NASDAQ TARS opened at $41.55 on Wednesday. The stock’s fifty day moving average is $42.00 and its 200 day moving average is $46.79. The stock has a market capitalization of $1.75 billion, a P/E ratio of -15.22 and a beta of 0.80. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.54 and a current ratio of 5.57. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TARS. Charles Schwab Investment Management Inc. raised its holdings in shares of Tarsus Pharmaceuticals by 1.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 293,700 shares of the company’s stock worth $16,262,000 after purchasing an additional 3,691 shares during the period. Victory Capital Management Inc. bought a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at $223,000. Raymond James Financial Inc. purchased a new stake in Tarsus Pharmaceuticals during the 4th quarter worth about $1,107,000. HighTower Advisors LLC bought a new position in Tarsus Pharmaceuticals in the 4th quarter worth about $207,000. Finally, Swiss National Bank grew its stake in Tarsus Pharmaceuticals by 1.2% during the fourth quarter. Swiss National Bank now owns 52,333 shares of the company’s stock valued at $2,898,000 after acquiring an additional 600 shares in the last quarter. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.